Bowles Danielle, Fry Darren
Veterinary Specialist Services, Brisbane, Queensland, Australia.
Compend Contin Educ Vet. 2011 Nov;33(11):E1.
Pimobendan, a calcium sensitizer and phosphodiesterase III inhibitor, has positive inotropic and vasodilatory properties. Its use in patients with naturally occurring congestive heart failure (CHF) has been studied in a number of blinded, randomized, multicenter clinical trials. It has been shown to improve quality of life, reduce heart insufficiency scores, and increase median survival times for patients with CHF due to dilated cardiomyopathy and myxomatous valvular disease. Although most studies have reported positive findings, some potential adverse effects have also been described. Studies are under way to further evaluate the effects of this novel positive inotrope and vasodilator in canine cardiac disease.
匹莫苯丹是一种钙增敏剂和磷酸二酯酶III抑制剂，具有正性肌力和血管舒张特性。在多项双盲、随机、多中心临床试验中，对其在自然发生的充血性心力衰竭（CHF）患者中的应用进行了研究。结果表明，它可改善生活质量，降低心力衰竭评分，并延长因扩张型心肌病和黏液瘤性瓣膜病导致的CHF患者的中位生存时间。尽管大多数研究报告了阳性结果，但也描述了一些潜在的不良反应。目前正在进行研究，以进一步评估这种新型正性肌力药和血管扩张剂对犬类心脏病的影响。
